Judgment;Information — ECLI:EU:T:2026:116
Date: 2026-02-11
Language of the case: English
Court formation: Fourth Chamber
Procedure: Action for annulment
Origin: Spain

Order of the President of the General Court of 29 February 2024 – Neuraxpharm Pharmaceuticals v Commission (Case T-1182/23 R) (Interim relief – Medicinal products for human use – Marketing authorisation for ‘Dimethyl fumarate Neuraxpharm – dimethyl fumarate’ – Application for suspension of operation of a measure – No urgency) Language of the case: English Parties Applicant: Neuraxpharm Pharmaceuticals, SL (Barcelona, Spain) (represented by: K. Roox, T. De Meese, J. Stuyck and C. Dumont, lawyers) Defendant: European Commission (represented by: A. Spina and E. Mathieu, acting as Agents) Re: By its application based on Articles 278 and 279 TFEU, the applicant seeks suspension of the operation of Commission Implementing Decision C(2023) 8921 final of 13 December 2023 revoking Commission Implementing Decision C(2022) 3254 final of 13 May 2022 granting marketing authorisation under Regulation (EC) No 726/2004 of the European Parliament and of the Council of 31 March 2004 laying down Union procedures for the authorisation and supervision of medicinal products for human use and establishing a European Medicines Agency (OJ 2004 L 136, p. 1), as amended, for ‘Dimethyl fumarate Neuraxpharm – dimethyl fumarate’, a medicinal product for human use. Operative part of the order 1. The application for interim relief is refused. 2. The costs are reserved. ____________